^
6ms
AK109-201: A Study of AK109 and AK104 in Advanced Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma (clinicaltrials.gov)
P1/2, N=138, Recruiting, Akeso | N=87 --> 138 | Trial completion date: Jan 2024 --> Jan 2027 | Trial primary completion date: Jul 2023 --> Oct 2025
Enrollment change • Trial completion date • Trial primary completion date • Metastases
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
6ms
Enrollment open • Metastases
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
8ms
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=198, Recruiting, Akeso | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Feb 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
Kaitanni (cadonilimab) • pulocimab (AK109)
9ms
New P3 trial
|
paclitaxel • Kaitanni (cadonilimab) • pulocimab (AK109)
2years
A Study of AK109 Combined With AK104 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=198, Recruiting, Akeso | Trial completion date: Oct 2023 --> Mar 2024 | Trial primary completion date: Aug 2022 --> Feb 2023
Trial completion date • Trial primary completion date • IO biomarker • Metastases
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Kaitanni (cadonilimab) • pulocimab (AK109)
3years
Clinical • New P1/2 trial • IO biomarker
|
PD-L1 (Programmed death ligand 1)
|
PD-L1 expression
|
Kaitanni (cadonilimab) • pulocimab (AK109)